Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRELAPSE: Aripiprazole Once Monthly vs Treatment as Usual in Early Schizophrenia
NCT02360319Phase 4Completed
- Sponsor
- Vanguard Research Group
- Start
- Dec 2014
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of aripiprazole in schizophrenia (2 arms), sponsored by Vanguard Research Group. Primary endpoint: Time to First Hospitalization at 24 months. Started Dec 2014; status: completed.
02
Drugs
aripiprazole
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02360319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02360319.